In order to prepare the substitution of a commercially available diagnostic kit, ProCOUNT (Becton Dickinson) or Stem-Kit (Coulter Immunotech), for our institutional protocol, we compared the three techniques for the numeration of CD34 ؉ progenitor cells in 50 peripheral blood and 51 apheresis samples, obtained from cancer patients or healthy donors. We show here that the three techniques yield results of the same order of magnitude. Although statistical analyses demonstrate significant differences between the three methods, these differences turned out to be clinically insignificant in most situations. Observed differences mostly affect samples with the highest content of CD34 ؉ cells, while the three assays provide equivalent results for values that are close to clinically relevant thresholds (20 ؋ 10 3 CD34
ming unit granulocyte-macrophage (CFU-GM), [4] [5] [6] and enumeration of CD34 ϩ cells by flow cytometry in peripheral blood, or in aphereses allows quantification of circulating or collected HPC faster than cell cultures. 7 The CD34 ϩ cell population contains all or most of the mature and immature progenitors. 8, 9 The CD34 ϩ cell number is an important factor for predicting both granulocyte and platelet recovery. 5, [10] [11] [12] [13] [14] Based on these publications and others, a dose of 2 ϫ 10 6 CD34 ϩ cells per kilogram of weight is usually considered as the minimal number to be collected for autologous transplantation.
Over the past years, several multicenter studies in Europe, North America and Australia demonstrated some variability in flow cytometric enumeration of CD34 ϩ HPC between different laboratories, and prompted the formulation of guidelines by several cooperative groups, including ISHAGE. [15] [16] [17] [18] [19] [20] Another problem associated with institutional protocols is that they use research reagents that have not been registered for diagnostic use. To facilitate the introduction of quality assurance in cell therapy laboratories, laboratory diagnostic companies designed CD34 ϩ cell numeration kits for in vitro diagnostic use. Examples of these are ProCOUNT (Becton Dickinson Immunocytometry System, BDIS, San Jose, CA, USA), and Stem-Kit (Beckman-Coulter, Marseille, France). In addition to providing solutions to the above problems, these two kits allow the measurement of the percentage and of the absolute number of CD34 ϩ cells directly from the flow cytometer, thus limiting the source of error to one automated analyzer. 21 This study was undertaken to compare ProCOUNT and Stem-Kit with our institutional (Institut Paoli-Calmettes, IPC) protocol, by assessing 50 peripheral blood samples and 51 apheresis samples obtained from mobilized patients or healthy donors.
Materials and methods

Study design
One hundred and one samples (50 peripheral blood samples and 51 apheresis samples) were randomly obtained after informed consent, from patients with various poor risk malignancies mobilized with chemotherapy and/or rhG-CSF (autologous HPC transplantation), or from healthy volunteer donors (allogeneic HPC transplantation). Peripheral blood samples were obtained by venipuncture, and col-lected into K 3 EDTA Vacutainer blood collection tubes (Becton Dickinson). Apheresis samples were anticoagulated with ACD. Samples were simultaneously assessed by the three methods. Data acquisition and analysis with Pro-COUNT or Stem-Kit were performed according to the manufacturers' recommendations. Reproducibility was evaluated on two samples with low and high CD34 ϩ cell contents (around 20 and 1800 CD34 ϩ cells/l) by performing 10 replicates. Mean values, standard deviations and coefficients of variation (CV%) were calculated for each method.
CD34
؉ staining and analysis: flow cytometry ϩ cells in apheresis products was a stain-wash no lysis method as previously described. 6 In peripheral blood samples, we used a lyse stain-wash-lyse method ( Table 1) . As we did not use fluorescent beads, absolute CD34 ϩ cell counts were calculated by multiplying total leukocyte counts obtained from a hematological analyzer (Coulter STKS), with the percentage of CD34 ϩ cells. For all three CD34 ؉ counts with three different protocols S Olivero et al 389 techniques, a FACScan flow cytometer (BDIS) equiped with three-color fluorescence was used. The ProCOUNT software is specifically designed by BDIS for data acquisition and analysis, and uses a multiple gating strategy. For Stem-Kit, and for our in-house technique, data acquisition and analysis were performed using the CellQuest software (BDIS), and specific and dedicated macro commands. Gating strategies were comparable for the two diagnostic kits and for our institutional protocol on aphereses, as illustrated in Figures 1, 2 and 3 . CD34 ϩ cells were counted within the low SSC, low to intermediate FSC, and CD45 ϩ electronic window. In addition, for ProCOUNT non-nucleated cells were excluded from analysis by the use of a nucleic acid dye, and for our institutional protocol, dead cells were excluded after staining with propidium iodide (Sigma-Aldrich, Germany). For peripheral blood, our institutional protocol simply measures the percentage of CD34 ϩ cells within the low to intermediate SSC cell population, by comparison with an irrelevant isotype-matched control (see Figure 3 ), a technique very similar to the one described by the Milan group. 22 Acquisition and analysis were performed on a minimum number of 50 000 events in each case.
Statistical analyses
Statistical analyses were carried out using the StatView software (Abacus Concepts, Berkeley, CA, USA). The degree of correlation between the three methods was evaluated using an analysis of variance (ANOVA). A significance level of 0.05 was used to judge statistically significant differences. When analysis of variance showed statistically significant differences between all three methods, comparisons between one method with each of the others were then carried out using a paired t-test. The lack of agreement between the two methods was evaluated by calculating the bias, estimated by the mean difference and the variability (ie standard deviation of the difference, s.d.d.) according to the Bland and Altman method. 23 For each sample, the difference between CD34 ϩ cell enumeration (method 1 Ϫ method 2) was plotted against the average CD34 ϩ cell number. whether biological differences would translate into different clinical decisions (level of significance of 0.05).
Results
ProCOUNT, Stem-Kit and the IPC protocol yield comparable results for CD34 ϩ cell percentage and absolute numbers in peripheral blood and apheresis samples
Fifty peripheral blood and 51 apheresis samples were assessed for the percentage and absolute number of CD34 ϩ cells, using three techniques in parallel. Inter-individual variations were responsible for a wide range of CD34 ϩ cell counts, both in peripheral blood and in aphereses, as shown in Figure 4 .
In peripheral blood, the average values for CD34 ϩ cell percentages were close with the three techniques (0.45, 0.49 and 0.47 for the IPC protocol, ProCOUNT and Stem-Kit, respectively), and were not significantly different ( Figure  4a ). ANOVA demonstrated a statistically significant difference in the absolute numbers of CD34 ϩ cells/ml, measured with the three techniques (P Ͻ 0.01); a paired t-test ( Figure  4b ) showed that differences were due to higher CD34 ϩ cell counts with Stem-Kit (60.4 ϫ 10 3 cells/ml), than with Pro-COUNT (54.6 ϫ 10 3 cells/ml, P Ͻ 0.01) or the IPC protocol (53.01 ϫ 10 3 CD34 ϩ cells/ml, P Ͻ 0.05). Differences were also observed for the leukocyte count (P Ͻ 0.001 between the three methods), and were due to a higher leukocyte count with Stem-Kit. The mean values were 23.37 ϫ Figure 5 Bland and Altman plots for method comparisons. On peripheral blood samples (a-c, upper line), major discordances affect only the highest results (higher than 20 ϫ 10 3 CD34 ϩ /ml). Around the threshold of interest of 20 ϫ 10 3 CD34 ϩ /ml used to initiate aphereses, the three methods provide very similar results. Differences were greater for apheresis samples (d-f, lower row), again mostly observed with the highest values (higher than 2 ϫ 10 6 CD34 ϩ /ml). 
CD34
ϩ cell numbers when compared with the IPC protocol or ProCOUNT.
In apheresis samples, a two-way ANOVA showed that CD34 ϩ cell percentages, CD34 ϩ cell absolute numbers, and total leukocyte counts all differed significantly between the three methods (P Ͻ 0.05, P Ͻ 0.01 and P Ͻ 0.001, respectively). In contrast with results observed with peripheral blood samples, percentages of CD34 ϩ cells (Figure 4d ) obtained with Stem-Kit (mean value: 1.31%) were significantly lower than those obtained with our institutional protocol (1.45%, P Ͻ 0.05), or with ProCOUNT (1.42%, P Ͻ 0.05). For CD34 ϩ cell numbers (Figure 4e) ϩ cells/ml when comparing our IPC protocol with ProCOUNT, Ϫ152.4 ϫ 10 3 CD34 ϩ cells/ml when comparing our IPC protocol with Stem-Kit, and Ϫ266.9 ϫ 10 3 CD34 ϩ cells/ml when comparing our Pro-COUNT with Stem-Kit ( Figure 5, lower row) . The s.d.d. were ϩ295.2 ϫ 10 3 CD34 ϩ cells/ml when comparing our IPC protocol with ProCOUNT, ϩ510 ϫ 10 3 CD34
ϩ cells/ml when comparing our IPC protocol with Stem-Kit, and 517.1 ϫ 10 3 CD34 ϩ cells/ml when comparing ProCO-UNT with Stem-Kit. This suggests that the three techniques produce significantly different results, with a difference between the IPC protocol and Stem-Kit, and a difference between the IPC protocol and ProCOUNT being comparable but of opposite signs.
To assay the reproducibility of CD34 ϩ cell numeration with the three techniques, 10 replicates of two different samples were evaluated with the three techniques. In one sample with a low CD34 ϩ cell content (close to 20 ϫ 10 3 CD34 ϩ cells/ml), the CV% for our laboratory's routine method was 13%, comparable to ProCOUNT, although it was 7% for Stem-Kit. On a high progenitor cell sample the CV% was 4.07% whereas CV% were 5.06% for ProCOUNT and 12.6% for Stem-Kit. Table 2 shows the distribution of patients in whom apheresis would have been started or not, based on the strict interpretation of a pre-established threshold of 20 ϫ 10 3
Biological differences are statistically significant, but would rarely lead to different clinical decisions
CD34
ϩ cells/ml in peripheral blood, depending on the method used to measure HPC. The figures differ by one patient only, thus suggesting that substituting one technique for another would lead to different clinical decisions in approximately 2% of situations.
Similarly, we looked at the number of patients for whom aphereses would have been discontinued or repeated, based on the strict interpretation of a threshold for accumulated numbers of HPC at 3 ϫ 10 6 CD34 ϩ cells/kg. As expected from the statistical analysis that is described above, and the observation that results obtained with Stem-Kit tend to be higher than results obtained with the IPC protocol or with ProCOUNT, approximately 10% of the patients would undergo one less apheresis if Stem-Kit was used rather than the IPC protocol, or ProCOUNT. This trend was not statistically significant, when using a 2 analysis.
Discussion
The number of HPC, measured as CD34 ϩ cells, in hematopoietic grafts, is one of the main parameters for predicting the length of hematopoietic recovery following autologous transplantation, and thus predicting the risk-benefit ratio associated with high-dose chemotherapy in cancer patients.
Enumeration of CD34
ϩ cells is based on staining of cells with labeled mAb to CD34, and flow cytometry. An alternative technology is the Steller assay (Biometric Imaging, Mountain View, CA, USA), that uses microvolume fluorimetry (MVF). Two studies designed to compare the Steller assay with ProCOUNT, 3 or with an institutional flow cytometry protocol 2, 3 showed a good correlation between all methods, and comparable linearity and reproducibility. The authors reported that MVF was easy to perform, faster than flow cytometry, and did not require highly trained staff.
Some variability in enumeration of CD34 ϩ cells by flow cytometry was demonstrated by several recent studies, due to variations in different aspects of the technique, including cell isolation on density gradient, or the use of a lysis procedure. 24 Also of importance are the nature of the CD34 mAb, the gating strategy 15, 25, 16 (particularly the use of an anti-CD45 mAb to identify leukocytes), and the number of counted events. 16, 25, 26 However, at least two studies in which variability in flow cytometry data was assessed, suggest that differences between distinct laboratories may be clinically insignificant. 27, 28 In addition, one report underlines the reliability of institutional protocols designed to numerate CD34 ϩ cells. 29 In any case, the use of a consensus technique may reduce inter-laboratory variability. [19] [20] [21] 26, 30 Guidelines have been proposed by working parties such as the Milan group 18, 22 and the ISHAGE committee 20 to promote standardization. More recently, laboratory diagnostic companies made available systems for absolute CD34 ϩ enumeration based on flow cytometry. Advantages associated with the use of these diagnostic kits are that they fulfill requirements for future registration with regulatory agencies, that the flow cytometer provides both the measurement of CD34 ϩ cell percentage, and of the absolute number, thus restricting the need for one analyzer rather than two, and finally provide instructions for cell staining, data acquisition and analysis that integrate most if not all of the above discussed guidelines. 20 Thus, they favor the introduction not only of standardization, but also of quality assurance in cell therapy facilities.
We show here that both in peripheral blood and apheresis samples, the three methods provide well correlated results. However, equivalence rather than correlation is the important observation when one prepares to substitute one method for another. Our results demonstrate that statistically significant differences exist between results obtained with the IPC protocol or laboratory diagnostics kits. In peripheral blood, these differences are mostly observed
CD34
؉ counts with three different protocols S Olivero et al 393 Table 2 Clinical consequences of using one method or another: the strict interpretation of pre-established thresholds would lead to different clinical decisions in a limited number of patients
IPC protocol
ProCOUNT Stem-Kit 31 these two MoAb are used separately in the IPC protocol. Finally, the gating strategy used in our protocol is close to the ISHAGE guidelines on the basis of which StemKit was designed. It is possible that the addition of these methodological differences may lead to the observed differences in results. However, the origin of differences between the three techniques rather lies in the absolute count of nucleated events, rather than in flow cytometric determination of CD34 ϩ cell percentages. More importantly, results yielded by all three methods were of the same order of magnitude. When considering values that are close to important thresholds for clinical decisions, observed differences turned out to be insignificant, except in a small proportion of patients. This proportion is even smaller, when one considers that the decision to start apheresis or the decision to accept or reject a cell product for transplantation, usually relies on a flexible interpretation of biological values, taking into account other parameters, such as disease status and patient general condition.
Our study also supports the view that institutional protocols can provide a highly reproducible determination of CD34 ϩ cell counts and percentages: we show here that the CV% for our laboratory's routine method is comparable or lower than CV% measured either for ProCOUNT or StemKit. This observation reinforces previously published reports. 29 One can argue that it is likely to be due to the greater familiarity of laboratory staff with our technique. However, the main advantage associated with the use of diagnostic kits may be in improving quality assurance, as much as in promoting standardization and inter-laboratory reproducibility. Finally, reproducibility in procedures and results does not guarantee that observed values are actual values: it is impossible to deduce from our work which one of the three techniques yields the most accurate result.
In conclusion, our comparative study evaluates three different techniques for the measurement of CD34 ϩ cell percentages and absolute numbers in peripheral blood and apheresis samples. It thus prepares for the substitution of diagnostic kits to institutional protocols in the practice of autologous and allogeneic blood cell transplantation for patients with cancers or hematological diseases.
